Health Care & Life Sciences » Pharmaceuticals | Shanghai Kaibao Pharmaceutical Co. Ltd.

Shanghai Kaibao Pharmaceutical Co. Ltd. | Mutual Funds

Mutual Funds that own Shanghai Kaibao Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
14,525,819
1.81%
0
0.13%
12/31/2017
Nanfang CSI 500 ETF
2,927,924
0.37%
24,900
0.11%
12/31/2017
2,257,004
0.28%
-108,591
0.8%
12/31/2017
Vanguard Emerging Markets Stock Index Fund
1,345,208
0.17%
0
0%
07/31/2018
596,000
0.07%
252,500
0.14%
12/31/2017
531,000
0.07%
531,000
1.13%
12/31/2017
454,611
0.06%
100,200
0.25%
12/31/2017
GF CSI 500 ETF
247,812
0.03%
-19,440
0.12%
12/31/2017
236,600
0.03%
63,300
0.77%
12/31/2017
Harvest CSI 500 ETF
175,551
0.02%
20,300
0.12%
12/31/2017

About Shanghai Kaibao Pharmaceutical Co.

View Profile
Address
No. 88, Chengpu Road
Shanghai Shanghai 201401
China
Employees -
Website http://www.xykb.com
Updated 07/08/2019
Shanghai Kaibao Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of modern Chinese medicine. Its medicines are in the form of injection, tablets, hard capsules, granules, mixture, syrup, oral liquid, and Chinese medicine extraction; such as Tanreqing injection, doxofylline capsule, Captopril sustained-release tablets, and Hydrochloride pioglitazone tablets. The company was founded on April 12, 2000 and is headquartered in Shanghai, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.